BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has reported promising clinical data for its product Bria-IMT™, showing significant progress in treating advanced breast cancer patients resistant to ADCs. The treatment demonstrated a progression-free survival rate of 4.2 months, which is double that of standard controls, and an impressive 71% intracranial response rate in patients with CNS metastases. These results suggest Bria-IMT™ could be a game-changer for patients with limited treatment options, offering a well-tolerated and effective therapy.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
